Cargando…

Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX

Studies have indicated an association between UDP‐glucuronosyltransferase‐1A1 (UGT1A1) genetic polymorphisms and irinotecan‐induced toxicity. We undertook this study to investigate the association between UGT1A1 genetic polymorphisms and toxicity in patients treated with the FOLFIRINOX (comprising o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirasu, Hiromichi, Todaka, Akiko, Omae, Katsuhiro, Fujii, Hirofumi, Mizuno, Nobumasa, Ozaka, Masato, Ueno, Hideki, Kobayashi, Satoshi, Uesugi, Kazuhiro, Kobayashi, Noritoshi, Hayashi, Hideyuki, Sudo, Kentaro, Okano, Naohiro, Horita, Yosuke, Kamei, Keiko, Yukisawa, Seigo, Kobayashi, Marina, Fukutomi, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361560/ https://www.ncbi.nlm.nih.gov/pubmed/30447099 http://dx.doi.org/10.1111/cas.13883

Ejemplares similares

Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2019)

FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study
por: Umemoto, Kumiko, et al.
Publicado: (2021)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study
por: Kawakami, Takeshi, et al.
Publicado: (2018)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis
por: Tezuka, Shun, et al.
Publicado: (2021)

Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
por: Maruki, Yuta, et al.
Publicado: (2020)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study
por: Sharma, Atul, et al.
Publicado: (2021)

The Sasaki-W anastomosis for recurrent Crohn’s disease stenosis after the Kono-S anastomosis
por: Asai, Takahiro, et al.
Publicado: (2023)

Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study
por: Keum, Jiyoung, et al.
Publicado: (2022)

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer
por: Yoshida, Kensaku, et al.
Publicado: (2017)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgroup analysis on systemic inflammatory response in JCOG1106
por: Mizuno, Nobumasa, et al.
Publicado: (2023)

UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan
por: Kimura, Kei, et al.
Publicado: (2018)

Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
por: Hasegawa, Sho, et al.
Publicado: (2022)

Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2018)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
por: Kunzmann, Volker, et al.
Publicado: (2014)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan‐related toxicities in patients with lung cancer
por: Fukuda, Minoru, et al.
Publicado: (2017)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
por: Sadaka, Shiori, et al.
Publicado: (2022)

A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer
por: Takahara, Naminatsu, et al.
Publicado: (2022)

Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options
por: Kurita, Yusuke, et al.
Publicado: (2022)

Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
por: Yoshikawa-Kimura, Akie, et al.
Publicado: (2022)

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Okusaka, Takuji, et al.
Publicado: (2015)

Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
por: Mita, Naoki, et al.
Publicado: (2021)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Shirakawa, Tsuyoshi, et al.
Publicado: (2023)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
por: Sawada, Masashi, et al.
Publicado: (2020)

The apiosyltransferase celery UGT94AX1 catalyzes the biosynthesis of the flavone glycoside apiin
por: Yamashita, Maho, et al.
Publicado: (2023)

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX
por: Kaga, Yasuhiro, et al.
Publicado: (2016)

Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy
por: Yamada, Yunami, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ktl3pbhdpt64f3gsj0fvb6hors